Shanghai Meiyue Biotech Development Co. Ltd. has discovered MAPK p38 inhibitors reported to be useful for the treatment of arthritis, psoriasis, systemic lupus erythematosus, diabetes, cancer, ...
Immuneering is set to progress its lead oncology candidate, atebimetinib, to the next stage of clinical development in both first-line pancreatic and non-small cell lung cancer (NSCLC). In ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback